M. Ladická

Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia

L. Dušek, R. Hájek, Z. Král, 2019, Journal of Cancer.

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial

L. Pleyer, R. Greil, U. Jäger, 2019, Cancer medicine.

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.

L. Pleyer, R. Greil, U. Jäger, 2016, The Lancet. Haematology.

Running title: Real-world effectiveness and safety of DVD in RRMM

Iveta, M. Mistrik, A. Vranovský, 2021 .

Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience.

J. Lakota, A. Vranovský, V. Ballová, 2008, Neoplasma.

Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial

R. Greil, U. Jäger, M. Steurer, 2014 .

New treatment options for cutaneous T-cell lymphomas

M. Ladická, 2022, Onkologie.

Tandem autologous stem cell transplantation in multiple myeloma after high-dose chemotherapy with two separate collections: single institution experience.

J. Lakota, Ľ. Drgoňa, A. Vranovský, 2012, Neoplasma.

Ibrutinib treatment of mantle cell lymphoma complicated by progressive multifocal leukoencephalopathy
.

P. Babál, Ľ. Drgoňa, L. Danihel, 2020, International journal of clinical pharmacology and therapeutics.